Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone212-733-2323
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$53.65 billion
Profitability
Miscellaneous
Employees92,400
Next Earnings Date1/28/2020 (Confirmed)
OptionableOptionable
Pfizer (NYSE:PFE) Frequently Asked Questions
What is Pfizer's stock symbol?
Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."
How often does Pfizer pay dividends? What is the dividend yield for Pfizer?
Pfizer announced a quarterly dividend on Monday, December 16th. Investors of record on Friday, January 31st will be paid a dividend of $0.38 per share on Friday, March 6th. This represents a $1.52 annualized dividend and a yield of 3.75%. The ex-dividend date of this dividend is Thursday, January 30th. This is an increase from Pfizer's previous quarterly dividend of $0.36. View Pfizer's Dividend History.
How will Pfizer's stock buyback program work?
Pfizer announced that its board has initiated a stock buyback program on Friday, December 14th 2018, which authorizes the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 3.8% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's leadership believes its shares are undervalued.
How were Pfizer's earnings last quarter?
Pfizer Inc. (NYSE:PFE) posted its quarterly earnings results on Tuesday, October, 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.62 by $0.13. The biopharmaceutical company had revenue of $12.68 billion for the quarter, compared to the consensus estimate of $12.37 billion. Pfizer had a net margin of 30.57% and a return on equity of 28.10%. Pfizer's revenue for the quarter was down 4.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.78 EPS. View Pfizer's Earnings History.
When is Pfizer's next earnings date?
How can I listen to Pfizer's earnings call?
Pfizer will be holding an earnings conference call on Tuesday, January 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Pfizer issued on next quarter's earnings?
Pfizer issued an update on its FY19 earnings guidance on Tuesday, October, 29th. The company provided earnings per share guidance of $2.94-3.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.82. The company issued revenue guidance of $51.2-52.2 billion, compared to the consensus revenue estimate of $51.47 billion.
What price target have analysts set for PFE?
12 Wall Street analysts have issued 1-year target prices for Pfizer's shares. Their forecasts range from $36.00 to $55.00. On average, they expect Pfizer's stock price to reach $43.86 in the next year. This suggests a possible upside of 8.3% from the stock's current price. View Analyst Price Targets for Pfizer.
What is the consensus analysts' recommendation for Pfizer?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.
What are Wall Street analysts saying about Pfizer stock?
Here are some recent quotes from research analysts about Pfizer stock:
- 1. According to Zacks Investment Research, "The Consumer Healthcare joint venture with Glaxo, the Array acquisition and the pending merger of Upjohn unit with Mylan, if successful, will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. The smaller Pfizer should see better revenue growth as the Lyrica LOE cliff will go away. Pfizer expects continued strong growth of key brands like Ibrance and Eliquis and biosimilars to drive sales in the second half. Pfizer is also strengthening its pipeline and hopes to launch new innovative medicines in the next five years, which can drive long-term growth. However, currency headwinds, weak sales in the sterile injectables portfolio, pricing pressure and some recent negative product developments for Prevnar and Xeljanz, are top-line headwinds. Shares have underperformed the industry this year so far. " (10/1/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and think respectable earnings growth, driven by Innovative Medicines, pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all underappreciated. Therefore, we believe multiple expansion and upward earnings revisions should drive PFE shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $53." (2/19/2019)
Has Pfizer been receiving favorable news coverage?
News coverage about PFE stock has been trending positive on Tuesday, InfoTrie reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pfizer earned a news impact score of 3.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for Pfizer.
Who are some of Pfizer's key competitors?
Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).
What other stocks do shareholders of Pfizer own?
Who are Pfizer's key executives?
Pfizer's management team includes the folowing people:
- Mr. Ian C. Read, Exec. Chairman (Age 65)
- Mr. Albert Bourla D.V.M., DVM, Ph.D., CEO & Director (Age 57)
- Mr. Frank A. D'Amelio, CFO & EVP of Global Supply & Bus. Operations (Age 61)
- Dr. Mikael Dolsten, Chief Scientific Officer & Pres of Worldwide Research, Devel. and Medical (Age 60)
- Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 54)
Who are Pfizer's major shareholders?
Pfizer's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include PGGM Investments (0.07%), Calamos Advisors LLC (0.06%), DNB Asset Management AS (0.06%), Gateway Investment Advisers LLC (0.04%), Nisa Investment Advisors LLC (0.04%) and Hexavest Inc. (0.04%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Charles H Hill, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View Institutional Ownership Trends for Pfizer.
Which major investors are selling Pfizer stock?
PFE stock was sold by a variety of institutional investors in the last quarter, including PGGM Investments, Artemis Investment Management LLP, Hexavest Inc., DNB Asset Management AS, Meag Munich Ergo Kapitalanlagegesellschaft MBH, State of Alaska Department of Revenue, Gateway Investment Advisers LLC and Huntington National Bank. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Mikael Dolsten and Rady A Johnson. View Insider Buying and Selling for Pfizer.
Which major investors are buying Pfizer stock?
PFE stock was acquired by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, New England Professional Planning Group Inc., Johanson Financial Advisors Inc., Donaldson Capital Management LLC, Commerzbank Aktiengesellschaft FI, Calamos Advisors LLC, Corbenic Partners LLC and Manning & Napier Group LLC. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc and Scott Gottlieb. View Insider Buying and Selling for Pfizer.
How do I buy shares of Pfizer?
Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Pfizer's stock price today?
One share of PFE stock can currently be purchased for approximately $40.51.
How big of a company is Pfizer?
Pfizer has a market capitalization of $224.19 billion and generates $53.65 billion in revenue each year. The biopharmaceutical company earns $11.15 billion in net income (profit) each year or $3.00 on an earnings per share basis. Pfizer employs 92,400 workers across the globe.View Additional Information About Pfizer.
What is Pfizer's official website?
How can I contact Pfizer?
Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.
MarketBeat Community Rating for Pfizer (NYSE PFE)
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
